{"id":387115,"date":"2020-11-23T16:08:05","date_gmt":"2020-11-23T21:08:05","guid":{"rendered":"http:\/\/www.marketnewsdesk.com\/?p=387115"},"modified":"2020-11-23T16:08:05","modified_gmt":"2020-11-23T21:08:05","slug":"antares-pharma-to-participate-in-the-piper-sandler-32nd-annual-virtual-healthcare-conference","status":"publish","type":"post","link":"https:\/\/www.marketnewsdesk.com\/index.php\/antares-pharma-to-participate-in-the-piper-sandler-32nd-annual-virtual-healthcare-conference\/","title":{"rendered":"Antares Pharma to Participate in the Piper Sandler 32nd Annual Virtual Healthcare Conference"},"content":{"rendered":"
\n

EWING, N.J., Nov. 23, 2020 (GLOBE NEWSWIRE) — Antares Pharma, Inc. (NASDAQ: ATRS) (\u201cthe Company\u201d), a pharmaceutical technology company, today announced that Robert F. Apple, President and Chief Executive Officer has participated in a fireside chat presentation and will host investor meetings at the Piper Sandler 32nd<\/sup> Annual Virtual Healthcare Conference being held on December 1-3, 2020.<\/p>\n

The pre-recorded webcast of the fireside chat will be available under the \u201cFor Investors\u201d section of the Antares Pharma website at www.antarespharma.com<\/a>.<\/p>\n

\n About Antares Pharma<\/strong>\n <\/p>\n

Antares Pharma, Inc. is a pharmaceutical technology company focused primarily on the development and commercialization of self-administered injectable pharmaceutical products using advanced drug delivery auto injector technology. The Company has a portfolio of proprietary and partnered commercial products with several product candidates in various stages of development, as well as significant strategic alliances with industry leading pharmaceutical companies including Teva Pharmaceutical Industries, Ltd. (Teva), Covis Pharma (Covis), Pfizer Inc. (Pfizer) and Idorsia Pharmaceuticals Ltd. (Idorsia). Antares Pharma\u2019s FDA-approved products include XYOSTED\u00ae<\/sup> (testosterone enanthate) injection, OTREXUP\u00ae<\/sup> (methotrexate) injection for subcutaneous use and Sumatriptan Injection USP, which is distributed by Teva. The Company also markets NOCDURNA\u00ae<\/sup> (desmopressin acetate) in the U.S., which was licensed from Ferring Pharmaceuticals.<\/p>\n

\n SAFE HARBOR STATEMENT UNDER THE PRIVATE SECURITIES LITIGATION REFORM ACT OF 1995<\/strong>\n <\/p>\n

\n This press release contains forward-looking statements within the meaning of the safe <\/strong>
\n harbor<\/strong>
\n provisions of the Private Securities Litigation Reform Act of 1995. Forward-looking statements are subject to certain risks and uncertainties that can cause actual results to differ materially from those described. Factors that may cause such differences include, but are not limited to: the Company\u2019s ability to achieve the 2020 full-year revenue guidance; <\/strong>
\n the uncertainty regarding the duration, scope and severity of the COVID-19 pandemic and the mitigation measures and other restrictions implemented in response to the same<\/strong>
\n and the impact on<\/strong>
\n demand for our products, <\/strong>
\n new patients and prescriptions, future revenue, <\/strong>
\n product supply, and our overall business, operating results and financial condition<\/strong>
\n ; successful commercialization of NOCDURNA<\/strong>
\n
\n \u00ae<\/strong>
\n <\/sup>
\n in the United States and market acceptance and future revenue from the same<\/strong>
\n : commercial success of <\/strong>
\n XYOSTED<\/strong>
\n
\n \u00ae<\/strong>
\n <\/sup>
\n and future revenue from the same;<\/strong>
\n market acceptance of Teva\u2019s generic epinephrine auto-injector product and future revenue from the same;<\/strong>
\n whether the FDA will withdraw marketing approval for <\/strong>
\n Covis<\/strong>
\n \u2019 <\/strong>
\n Makena<\/strong>
\n
\n \u00ae<\/strong>
\n <\/sup>
\n subcutaneous auto injector following the recent FDA letter seeking withdrawal, whether <\/strong>
\n Covis<\/strong>
\n will be granted an appeal hearing and if granted, whether <\/strong>
\n Covis<\/strong>
\n will be successful and <\/strong>
\n future prescriptions, market acceptance and revenue from the same; Teva\u2019s ability to successfully commercialize VIBEX<\/strong>
\n
\n \u00ae<\/strong>
\n <\/sup>
\n Sumatriptan Injection USP and the amount of revenue from the same; future prescriptions and sales of OTREXUP<\/strong>
\n
\n \u00ae<\/strong>
\n <\/sup>
\n ; Teva\u2019s ability to successfully commercialize generic teriparatide in 11 countries in Europe, Canada and Israel and future revenue from the same, successful development including the timing and results of the clinical bridging and Phase 3 clinical trial <\/strong>
\n of the drug device combination product for <\/strong>
\n Selatogrel<\/strong>
\n with Idorsia Pharmaceuticals and FDA and global regulatory approvals and future revenue from the same; FDA approval of Teva\u2019s pending ANDA for generic <\/strong>
\n Forteo<\/strong>
\n and future revenue from the same; the timing and results of the Company\u2019s or its partners\u2019 research projects or clinical trials of product candidates in development including Pfizer\u2019s undisclosed development product; actions by the FDA or other regulatory agencies with respect to the Company\u2019s products or product candidates of its partners; continued growth in product, development, licensing and royalty revenue; the Company\u2019s ability to meet loan extension and interest only payment milestones and the ability to repay the debt obligation to Hercules Capital; the Company\u2019s ability to obtain financial and other resources for its research, development, clinical, and commercial activities and other statements regarding matters that are not historical facts, and involve predictions. These statements involve known and unknown risks, uncertainties and other factors that may cause actual results, performance, achievements or prospects to be materially different from any future results, performance, achievements or prospects expressed in or implied by such forward-looking statements. In some cases you can identify forward-looking statements by terminology such as ”may”, ”will”, ”should”, ”would”, ”expect”, ”intend”, ”plan”, ”anticipate”, ”believe”, ”estimate”, ”predict”, ”potential”, ”seem”, ”seek”, ”future”, ”continue”, or ”appear” or the negative of these terms or similar expressions, although not all forward-looking statements contain these identifying words. Additional information concerning these and other factors that may cause actual results to differ materially from those anticipated in the forward-looking statements is contained in the “Risk Factors” section of the Company’s Annual Report on Form 10-K, and in the Company’s other periodic reports and filings with the Securities and Exchange Commission. The Company cautions investors not to place undue reliance on the forward-looking statements contained in this press release. All forward-looking statements are based on information currently available to the Company on the date hereof, and the Company undertakes no obligation to revise or update these forward-looking statements to reflect events or circumstances after the date of this press release, except as required by law.<\/strong>\n <\/p>\n

\n Contact:<\/strong>
\n
Tram Bui
Vice President, Corporate Communications and Investor Relations
609-359-3016
tbui@antarespharma.com<\/a>\u00a0<\/p>\n

\n
\n
\n \n <\/div>\n

<\/div>\n","protected":false},"excerpt":{"rendered":"

EWING, N.J., Nov. 23, 2020 (GLOBE NEWSWIRE) — Antares Pharma, Inc. (NASDAQ: ATRS) (\u201cthe Company\u201d), a pharmaceutical technology company, today announced that Robert F. Apple, President and Chief Executive Officer has participated in a fireside chat presentation and will host investor meetings at the Piper Sandler 32nd Annual Virtual Healthcare Conference being held on December 1-3, 2020. The pre-recorded webcast of the fireside chat will be available under the \u201cFor Investors\u201d section of the Antares Pharma website at www.antarespharma.com. About Antares Pharma Antares Pharma, Inc. is a pharmaceutical technology company focused primarily on the development and commercialization of self-administered injectable pharmaceutical products using advanced drug delivery auto injector technology. The Company has a portfolio of proprietary and partnered commercial products … <\/p>\n

Continue reading “Antares Pharma to Participate in the Piper Sandler 32nd Annual Virtual Healthcare Conference”<\/span><\/a><\/p>\n","protected":false},"author":2,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[],"tags":[],"class_list":["post-387115","post","type-post","status-publish","format-standard","hentry"],"yoast_head":"\nAntares Pharma to Participate in the Piper Sandler 32nd Annual Virtual Healthcare Conference - Market Newsdesk<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.marketnewsdesk.com\/index.php\/antares-pharma-to-participate-in-the-piper-sandler-32nd-annual-virtual-healthcare-conference\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Antares Pharma to Participate in the Piper Sandler 32nd Annual Virtual Healthcare Conference - Market Newsdesk\" \/>\n<meta property=\"og:description\" content=\"EWING, N.J., Nov. 23, 2020 (GLOBE NEWSWIRE) — Antares Pharma, Inc. (NASDAQ: ATRS) (\u201cthe Company\u201d), a pharmaceutical technology company, today announced that Robert F. Apple, President and Chief Executive Officer has participated in a fireside chat presentation and will host investor meetings at the Piper Sandler 32nd Annual Virtual Healthcare Conference being held on December 1-3, 2020. The pre-recorded webcast of the fireside chat will be available under the \u201cFor Investors\u201d section of the Antares Pharma website at www.antarespharma.com. About Antares Pharma Antares Pharma, Inc. is a pharmaceutical technology company focused primarily on the development and commercialization of self-administered injectable pharmaceutical products using advanced drug delivery auto injector technology. The Company has a portfolio of proprietary and partnered commercial products … Continue reading "Antares Pharma to Participate in the Piper Sandler 32nd Annual Virtual Healthcare Conference"\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.marketnewsdesk.com\/index.php\/antares-pharma-to-participate-in-the-piper-sandler-32nd-annual-virtual-healthcare-conference\/\" \/>\n<meta property=\"og:site_name\" content=\"Market Newsdesk\" \/>\n<meta property=\"article:published_time\" content=\"2020-11-23T21:08:05+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODA5MDkxMyMzODQwNDI3IzIwMTk1NjA=\" \/>\n<meta name=\"author\" content=\"Newsdesk\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Newsdesk\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"4 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/antares-pharma-to-participate-in-the-piper-sandler-32nd-annual-virtual-healthcare-conference\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/antares-pharma-to-participate-in-the-piper-sandler-32nd-annual-virtual-healthcare-conference\\\/\"},\"author\":{\"name\":\"Newsdesk\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"headline\":\"Antares Pharma to Participate in the Piper Sandler 32nd Annual Virtual Healthcare Conference\",\"datePublished\":\"2020-11-23T21:08:05+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/antares-pharma-to-participate-in-the-piper-sandler-32nd-annual-virtual-healthcare-conference\\\/\"},\"wordCount\":854,\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/antares-pharma-to-participate-in-the-piper-sandler-32nd-annual-virtual-healthcare-conference\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=ODA5MDkxMyMzODQwNDI3IzIwMTk1NjA=\",\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/antares-pharma-to-participate-in-the-piper-sandler-32nd-annual-virtual-healthcare-conference\\\/\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/antares-pharma-to-participate-in-the-piper-sandler-32nd-annual-virtual-healthcare-conference\\\/\",\"name\":\"Antares Pharma to Participate in the Piper Sandler 32nd Annual Virtual Healthcare Conference - Market Newsdesk\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/antares-pharma-to-participate-in-the-piper-sandler-32nd-annual-virtual-healthcare-conference\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/antares-pharma-to-participate-in-the-piper-sandler-32nd-annual-virtual-healthcare-conference\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=ODA5MDkxMyMzODQwNDI3IzIwMTk1NjA=\",\"datePublished\":\"2020-11-23T21:08:05+00:00\",\"author\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"breadcrumb\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/antares-pharma-to-participate-in-the-piper-sandler-32nd-annual-virtual-healthcare-conference\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/antares-pharma-to-participate-in-the-piper-sandler-32nd-annual-virtual-healthcare-conference\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/antares-pharma-to-participate-in-the-piper-sandler-32nd-annual-virtual-healthcare-conference\\\/#primaryimage\",\"url\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=ODA5MDkxMyMzODQwNDI3IzIwMTk1NjA=\",\"contentUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=ODA5MDkxMyMzODQwNDI3IzIwMTk1NjA=\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/antares-pharma-to-participate-in-the-piper-sandler-32nd-annual-virtual-healthcare-conference\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Antares Pharma to Participate in the Piper Sandler 32nd Annual Virtual Healthcare Conference\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\",\"name\":\"Market Newsdesk\",\"description\":\"Latest Business News in Real Time\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\",\"name\":\"Newsdesk\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"caption\":\"Newsdesk\"},\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/author\\\/newsdesk\\\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Antares Pharma to Participate in the Piper Sandler 32nd Annual Virtual Healthcare Conference - Market Newsdesk","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.marketnewsdesk.com\/index.php\/antares-pharma-to-participate-in-the-piper-sandler-32nd-annual-virtual-healthcare-conference\/","og_locale":"en_US","og_type":"article","og_title":"Antares Pharma to Participate in the Piper Sandler 32nd Annual Virtual Healthcare Conference - Market Newsdesk","og_description":"EWING, N.J., Nov. 23, 2020 (GLOBE NEWSWIRE) — Antares Pharma, Inc. (NASDAQ: ATRS) (\u201cthe Company\u201d), a pharmaceutical technology company, today announced that Robert F. Apple, President and Chief Executive Officer has participated in a fireside chat presentation and will host investor meetings at the Piper Sandler 32nd Annual Virtual Healthcare Conference being held on December 1-3, 2020. The pre-recorded webcast of the fireside chat will be available under the \u201cFor Investors\u201d section of the Antares Pharma website at www.antarespharma.com. About Antares Pharma Antares Pharma, Inc. is a pharmaceutical technology company focused primarily on the development and commercialization of self-administered injectable pharmaceutical products using advanced drug delivery auto injector technology. The Company has a portfolio of proprietary and partnered commercial products … Continue reading \"Antares Pharma to Participate in the Piper Sandler 32nd Annual Virtual Healthcare Conference\"","og_url":"https:\/\/www.marketnewsdesk.com\/index.php\/antares-pharma-to-participate-in-the-piper-sandler-32nd-annual-virtual-healthcare-conference\/","og_site_name":"Market Newsdesk","article_published_time":"2020-11-23T21:08:05+00:00","og_image":[{"url":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODA5MDkxMyMzODQwNDI3IzIwMTk1NjA=","type":"","width":"","height":""}],"author":"Newsdesk","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Newsdesk","Est. reading time":"4 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/antares-pharma-to-participate-in-the-piper-sandler-32nd-annual-virtual-healthcare-conference\/#article","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/antares-pharma-to-participate-in-the-piper-sandler-32nd-annual-virtual-healthcare-conference\/"},"author":{"name":"Newsdesk","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"headline":"Antares Pharma to Participate in the Piper Sandler 32nd Annual Virtual Healthcare Conference","datePublished":"2020-11-23T21:08:05+00:00","mainEntityOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/antares-pharma-to-participate-in-the-piper-sandler-32nd-annual-virtual-healthcare-conference\/"},"wordCount":854,"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/antares-pharma-to-participate-in-the-piper-sandler-32nd-annual-virtual-healthcare-conference\/#primaryimage"},"thumbnailUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODA5MDkxMyMzODQwNDI3IzIwMTk1NjA=","inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/antares-pharma-to-participate-in-the-piper-sandler-32nd-annual-virtual-healthcare-conference\/","url":"https:\/\/www.marketnewsdesk.com\/index.php\/antares-pharma-to-participate-in-the-piper-sandler-32nd-annual-virtual-healthcare-conference\/","name":"Antares Pharma to Participate in the Piper Sandler 32nd Annual Virtual Healthcare Conference - Market Newsdesk","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/antares-pharma-to-participate-in-the-piper-sandler-32nd-annual-virtual-healthcare-conference\/#primaryimage"},"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/antares-pharma-to-participate-in-the-piper-sandler-32nd-annual-virtual-healthcare-conference\/#primaryimage"},"thumbnailUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODA5MDkxMyMzODQwNDI3IzIwMTk1NjA=","datePublished":"2020-11-23T21:08:05+00:00","author":{"@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"breadcrumb":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/antares-pharma-to-participate-in-the-piper-sandler-32nd-annual-virtual-healthcare-conference\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.marketnewsdesk.com\/index.php\/antares-pharma-to-participate-in-the-piper-sandler-32nd-annual-virtual-healthcare-conference\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/antares-pharma-to-participate-in-the-piper-sandler-32nd-annual-virtual-healthcare-conference\/#primaryimage","url":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODA5MDkxMyMzODQwNDI3IzIwMTk1NjA=","contentUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODA5MDkxMyMzODQwNDI3IzIwMTk1NjA="},{"@type":"BreadcrumbList","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/antares-pharma-to-participate-in-the-piper-sandler-32nd-annual-virtual-healthcare-conference\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/www.marketnewsdesk.com\/"},{"@type":"ListItem","position":2,"name":"Antares Pharma to Participate in the Piper Sandler 32nd Annual Virtual Healthcare Conference"}]},{"@type":"WebSite","@id":"https:\/\/www.marketnewsdesk.com\/#website","url":"https:\/\/www.marketnewsdesk.com\/","name":"Market Newsdesk","description":"Latest Business News in Real Time","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.marketnewsdesk.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979","name":"Newsdesk","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","caption":"Newsdesk"},"url":"https:\/\/www.marketnewsdesk.com\/index.php\/author\/newsdesk\/"}]}},"_links":{"self":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/387115","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/comments?post=387115"}],"version-history":[{"count":0,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/387115\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/media?parent=387115"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/categories?post=387115"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/tags?post=387115"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}